Cargando…
Corrigendum: Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study
Autores principales: | Moreira, Thais G., Matos, Kimble T. F., De Paula, Giovana S., Santana, Thais M. M., Da Mata, Raquel G., Pansera, Fernando C., Cortina, Andre S., Spinola, Marcelle G., Baecher-Allan, Clare M., Keppeke, Gerson D., Jacob, Jules, Palejwala, Vaseem, Chen, Karen, Izzy, Saef, Healey, Brian C., Rezende, Rafael M., Dedivitis, Rogerio A., Shailubhai, Kunwar, Weiner, Howard L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790742/ https://www.ncbi.nlm.nih.gov/pubmed/35095916 http://dx.doi.org/10.3389/fimmu.2021.815812 |
Ejemplares similares
-
Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study
por: Moreira, Thais G., et al.
Publicado: (2021) -
Nasal administration of anti-CD3 mAb (Foralumab) downregulates NKG7 and increases TGFB1 and GIMAP7 expression in T cells in subjects with COVID-19
por: G. Moreira, Thais, et al.
Publicado: (2023) -
Plecanatide-mediated activation of guanylate cyclase-C suppresses inflammation-induced colorectal carcinogenesis in Apc(+/Min-FCCC) mice
por: Chang, Wen-Chi L, et al.
Publicado: (2017) -
Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-C in rat models
por: Boulete, Illona-Marie, et al.
Publicado: (2018) -
Nasal administration of anti-CD3 monoclonal antibody modulates effector CD8+ T cell function and induces a regulatory response in T cells in human subjects
por: Chitnis, Tanuja, et al.
Publicado: (2022)